Insights into China’s Pharmaceutical Industry Trends from a 2,000-strong Industry Conference Sep 30, 2021 Life Science
RepliCel and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents Sep 16, 2021 Life Science
Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years Sep 14, 2021 Life Science
RepliCel Applies for Manufacturing Approval for its Collagen and Tissue Regeneration Cell Therapies Jul 7, 2021 Life Science
Hemostemix Provides Update of Phase II Clinical Trial, 9th Circuit Court Decision Including Cost Award and its Annual General Meeting Results Jul 6, 2021 Life Science
Increasing Sales and Expanding Markets: Learn about Milestone’s diagnostic and therapeutic injection technologies Jun 7, 2021 Life Science
Hemostemix Announces that, Due to the COVID-19 Pandemic, the Annual and Special Meeting Will Only Be Held via Zoom and Shareholders are Requested to Follow the Meeting Instructions Mailed to the Shareholders of Record May 31, 2021 Life Science
Hemostemix Announces the TSX Venture’s Preliminary Approval of the Closing of a $2,500,000 Convertible Debenture at $0.40 per Unit and Corporate Update May 29, 2021 Life Science
